US 11,673,872 B2
Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors
Hans Roland Lönn, Cheshire (GB); Stephen Connolly, Cheshire (GB); Steven Swallow, Cheshire (GB); Staffan Po Karlsson, Mölndal (SE); Carl-Johan Aurell, Mölndal (SE); John Fritiof Pontén, Cheshire (GB); Kevin James Doyle, Essex (GB); Amanda Jane Van De Poël, Essex (GB); Graham Peter Jones, Essex (GB); David Wyn Watson, Essex (GB); Jaqueline Anne Macritchie, Essex (GB); and Nicholas John Palmer, Cheshire (GB)
Assigned to AstraZeneca AB, Södertälje (SE)
Filed by AstraZeneca AB, Södertälje (SE)
Filed on Sep. 16, 2022, as Appl. No. 17/946,112.
Application 17/946,112 is a continuation of application No. 17/170,641, filed on Feb. 8, 2021.
Application 17/170,641 is a continuation of application No. 16/855,522, filed on Apr. 22, 2020, granted, now 11,117,874, issued on Sep. 14, 2021.
Application 16/855,522 is a continuation of application No. 16/358,091, filed on Mar. 19, 2019, granted, now 10,669,245, issued on Jun. 2, 2020.
Application 16/358,091 is a continuation of application No. 15/708,634, filed on Sep. 19, 2017, granted, now 10,287,258, issued on May 14, 2019.
Application 15/708,634 is a continuation of application No. 15/346,411, filed on Nov. 8, 2016, granted, now 9,815,805, issued on Nov. 14, 2017.
Application 15/346,411 is a continuation of application No. 14/601,371, filed on Jan. 21, 2015, granted, now 9,522,894, issued on Dec. 20, 2016.
Claims priority of provisional application 61/931,090, filed on Jan. 24, 2014.
Prior Publication US 2023/0115170 A1, Apr. 13, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 267/10 (2006.01); C07D 409/10 (2006.01); C07D 413/10 (2006.01); C07D 413/12 (2006.01); C07D 413/14 (2006.01); C07D 417/12 (2006.01); A61P 11/00 (2006.01); A61K 31/553 (2006.01); A61K 45/06 (2006.01)
CPC C07D 267/10 (2013.01) [A61K 31/553 (2013.01); A61K 45/06 (2013.01); C07D 413/12 (2013.01); C07D 413/14 (2013.01); C07D 417/12 (2013.01)] 14 Claims
 
1. Crystal form C of (2S)—N-{(1S)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide:

OG Complex Work Unit Chemistry
having X-ray powder diffraction peaks (° 2Θ) at 9.0±0.1, 14.0±0.1, 16.0±0.1, 16.4±0.1 and 21.0±0.1.